thalidomide has been researched along with Nasopharyngeal Carcinoma in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT)." | 9.51 | Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial. ( Hu, K; Jiang, L; Liang, L; Lin, Z; Liu, Z; Ning, X; Shi, Z; Wang, H; Wang, R; Wei, Y; Yan, H; Zhu, H, 2022) |
| "This multicenter clinical trial was designed to evaluate the efficacy and safety of thalidomide (THD) in preventing oral mucositis (OM) in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT)." | 5.51 | Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial. ( Hu, K; Jiang, L; Liang, L; Lin, Z; Liu, Z; Ning, X; Shi, Z; Wang, H; Wang, R; Wei, Y; Yan, H; Zhu, H, 2022) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 5.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 1.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, L | 1 |
| Liu, Z | 1 |
| Zhu, H | 1 |
| Wang, H | 1 |
| Wei, Y | 1 |
| Ning, X | 1 |
| Shi, Z | 1 |
| Jiang, L | 1 |
| Lin, Z | 1 |
| Yan, H | 1 |
| Wang, R | 1 |
| Hu, K | 1 |
| Xu, G | 1 |
| Wang, B | 1 |
| Yang, M | 1 |
| Qian, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Immunonutrients in Reducing Oral Mucositis in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multicenter, Randomized Controlled Clinical Trial[NCT05892354] | 190 participants (Anticipated) | Interventional | 2023-06-10 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Humans; Nasopharyngeal | 2022 |
1 other study available for thalidomide and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasophary | 2015 |